Atea Pharmaceuticals, Inc. Quarterly Income Tax Expense (Benefit) in USD from Q2 2021 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Atea Pharmaceuticals, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q2 2021 to Q2 2024.
  • Atea Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $243K, a 3.19% decline year-over-year.
  • Atea Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was $1.04M.
  • Atea Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2023 was $1.02M.
  • Atea Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2022 was -$3.59M, a 121% decline from 2021.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $1.04M $243K -$8K -3.19% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $1.05M $231K +$34K +17.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 $1.02M $349K +$226K +184% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 $792K $221K +$4.05M Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-08
Q2 2023 -$3.26M $251K +$131K +109% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 -$3.39M $197K +$197K Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$3.59M $123K Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 -$3.83M -$9.93M -163% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $120K -$7.08M -98.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $0 Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q3 2021 $6.1M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $7.2M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.